DNA2.0, Inc., the leading California-based bioengineering company, today announced the opening of its European branch office in Basel, Switzerland. The expansion is part of DNA2.0’s long term commitment to better serve its clients in both domestic and international markets. “We are thrilled to see more and more customers in Europe have utilized DNA2.0’s gene synthesis and GPS bioengineering technology for their research,” said Dr. Claes Gustafsson, Chief Commercial Officer of DNA2.0. “Combining gene synthesis and machine learning, we have built a proven platform which is being applied to engineer better genes, proteins, vectors, pathways, and even genomes.”
“Our investment in Europe reflects the strong growth we see in demand for DNA2.0’s technology at European biotechnology and pharmaceutical companies as well as universities,” said Greg Fujii, Senior Director of Sales and Head of DNA2.0 European Office. “Our Basel office will allow us to provide the same convenience and high quality customer support to our strong European customer base as our U.S. customers already enjoy.”
About DNA2.0:
DNA2.0 is the leading bioengineering solutions provider, offering an integrated pipeline of solutions including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering. DNA2.0 explores novel applications for synthetic genes and the synergy between efficient gene design and protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Newark, California. For more information, please visit http://www.DNA20.com.